FAMILIES FIGHT FOR RECOGNITION OF 9/11 CANCER VICTIMS
The ongoing struggle of families seeking recognition and compensation for 9/11 first responders who developed cancer shortly after their exposure at Ground Zero weighs heavily this September 11. The World Trade Center Health Program’s cancer latency policy requires a minimum four-year period between exposure and diagnosis for most cancers to be considered linked to 9/11. This policy has left some families, like the Skibas, ineligible for federal benefits because their loved ones were diagnosed before September 11, 2005. The families are fighting not just for financial compensation, but for acknowledgment of their loved ones’ sacrifices. The article highlights the challenges in determining accurate latency periods for 9/11-related cancers and the emotional toll the appeals process takes on families. Despite multiple appeals and reviews of the policy, many families remain excluded from federal recognition. The World Trade Center Health Program is currently reviewing literature to determine if changes to the latency policy are warranted. (New York Times)
SOUTH ASIAN HEART DISEASE PARADOX: GENETICS OR ENVIRONMENT?
Epidemiologist Mohammed Ali, influenced by early heart disease in his family, has explored the high prevalence of cardiovascular issues among South Asians. This group, encompassing countries like India, Pakistan, and Bangladesh, faces disproportionately high heart disease rates despite low rates of common risk factors like smoking. The “South Asian paradox” highlights this unexplained risk, leading to research focusing on genetic and environmental factors. Recent projects, such as India’s 10,000 genomes effort and the US National Heart, Lung and Blood Institute’s study, aim to uncover genetic contributions. However, concerns persist that emphasizing genetics might oversimplify the issue and ignore socio-economic and environmental factors. Researchers advocate for a balanced approach, integrating genetic findings with socio-behavioral insights to better address South Asian heart health disparities. Despite promising genetic research, effective interventions require attention to both genetic and non-genetic risk factors. (Nature)
If you’re enjoying the Daily Dose, sign up for the Daily Dose Newsletter and get the morning’s best science news from around the web delivered straight to your inbox? It’s easy like Sunday morning.
FINAL PHASE OF GAZA POLIO VACCINATION CAMPAIGN UNDERWAY
The 12-day polio vaccination campaign in Gaza has reached its final phase, targeting around 150,000 children in the northern region. The initiative, which started with successful phases in central and southern Gaza, has been notable for the humanitarian pauses allowing vaccination efforts amid ongoing conflict. The campaign, led by the Palestinian Ministry of Health and supported by UN agencies, aims to inoculate 640,000 children against a vaccine-derived poliovirus strain. Given the war’s displacement of families and Gaza’s poor sanitary conditions, achieving over 90% coverage is critical but challenging. The virus likely spread before detection in July, exacerbated by the area’s conditions. Despite logistical and security obstacles, including restrictions and continuous conflict, the campaign’s success hinges on sustained pauses and effective vaccination efforts. The overarching goal remains to prevent the virus’s spread beyond Gaza, highlighting the urgency for peace in the region. (Science)
SECURITY RESEARCHER EXPLOITS WHOIS LOOPHOLE REVEALING VULNERABILITIES
Recently, security researcher Benjamin Harris exploited a loophole by acquiring the expired domain dotmobilregistry.net, which had previously been the WHOIS server for .mobi domains. By setting up his own WHOIS server on this domain, Harris accessed sensitive systems and information, including email tracking and the ability to generate counterfeit HTTPS certificates. His rogue server received millions of queries from major organizations and governments, revealing vulnerabilities in the trust placed in WHOIS systems and certificate authorities. Harris’s setup allowed him to manipulate certificate issuance processes and monitor email activity, highlighting the fragile state of internet security. Despite ethical concerns, Harris’s discovery underscores the risks associated with outdated and mismanaged digital infrastructure, with ongoing investigations by security organizations to mitigate these threats. (Ars Technica)
GENENTECH MERGES CANCER RESEARCH DEPARTMENTS TO BOOST EFFICIENCY
Genentech recently merged its cancer immunology and molecular oncology research departments into a unified cancer research entity within Genentech Research and Early Development (gRED). Aviv Regev, head of gRED, stated that this reorganization was driven by scientific considerations. Previously, molecular oncology focused on cancer cells, while immunology addressed other cells, but recent research highlights the importance of interactions within the tumor ecosystem. By consolidating these departments, Genentech aims to enhance its scientific approach and efficiency, similar to past reorganizations in computational sciences. The restructuring follows a challenging period for Genentech, including setbacks with its anti-TIGIT program and the termination of a cell therapy collaboration. Regev hinted that while future changes might occur, they would be made cautiously and infrequently. (Fierce Biotech)
SYDNEY COMPANY DEVELOPS WEARABLE DEVICE FOR ADHD TREATMENT
Neurode, a Sydney-based company, has developed a novel wearable headband designed to track and treat ADHD symptoms. The device, which requires just 20 minutes of use per day, employs light electrical stimulation to the prefrontal cortex to balance brain activity and alleviate symptoms such as lack of focus. It also monitors brain activity changes using light. The concept was founded by Nathalie Gouailhardou, a neuroscientist who has lived with ADHD since childhood. Frustrated by the ineffectiveness of stimulant medications and their side effects, she envisioned a non-invasive solution after working with fNIRS technology at Bionics Institute. Gouailhardou, along with co-founder Damian Sofrevski, developed a smaller, more affordable version of this technology. Founded in 2021, Neurode has secured $3.5 million in pre-seed funding from Khosla Ventures and PsyMed Ventures. The device is currently in private beta, with the goal of gaining FDA approval. Khosla Ventures’ Alex Morgan highlighted the potential for innovation in ADHD treatment and praised Neurode’s approach for making advanced technology accessible and practical for home use. Neurode’s technology could also be applied to other conditions, such as age-related cognitive decline and depression. (Tech Crunch)
NYC LIVE ANIMAL MARKETS UNDER SCRUTINY FOR DISEASE RISKS
New York City’s live animal markets, with about 70 establishments, face scrutiny for their potential role in spreading zoonotic diseases. Overcrowded cages, poor waste management, and close proximity between species create a high-risk environment for disease transmission. The recent bird flu outbreaks, which led to market closures, underscore these concerns. Despite regulations for testing and disinfection, enforcement is weak, and violations are frequent. Experts, including Ann Linder from Harvard Law School, warn that these markets could be breeding grounds for new pathogens, similar to the Wuhan market linked to the coronavirus pandemic. Political and religious opposition complicates regulatory efforts, but recommendations include stricter hygiene practices, better species separation, and enhanced protective measures. Balancing public health with cultural practices remains a challenging issue as the city considers stronger oversight to prevent future outbreaks. (New York Times)
Thanks for reading. Let’s be careful out there.
WORDS: The Biology Guy.
IMAGE CREDIT: Lars Mulder.
Leave a Reply